Multiple sclerosis : clinical and laboratory research
-
Randomized Controlled Trial
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.
The purpose of this study was to determine the effects of oral teriflunomide on multiple sclerosis (MS) pathology inferred by magnetic resonance imaging (MRI). ⋯ Teriflunomide provided benefits on brain MRI activity across multiple measures, with a dose effect evident on several markers. These effects were also consistent across selected subgroups of the study population. These findings complement clinical data showing significant teriflunomide-related reductions in relapse rate and disease progression, and demonstrate containment of MRI-defined disease progression.
-
Randomized Controlled Trial
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
Alemtuzumab is a monoclonal antibody directed against CD52 that depletes T and B lymphocytes. ⋯ Alemtuzumab was associated with a greater chance of improved contrast sensitivity in patients with RRMS and may delay the worsening of visual function. Contrast sensitivity testing was sensitive to treatment effects, even within an active comparator study design. These results support the validity of low-contrast vision testing as a clinical outcome in MS trials.